larotrectinib
bayer
['larotrectinib']
patients with trk fusion positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up. #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.